340 related articles for article (PubMed ID: 21497067)
1. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
[TBL] [Abstract][Full Text] [Related]
2. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
[TBL] [Abstract][Full Text] [Related]
7. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
13. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
15. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
Stein GE; Schooley S; Peloquin CA; Missavage A; Havlichek DH
J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
Leonard SN; Rossi KL; Newton KL; Rybak MJ
J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
[TBL] [Abstract][Full Text] [Related]
19. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]